Industry news

Small is big: Pharma’s R&D brain drain continues as GSK’s Chris Carpenter jumps to upstart Rubius

John Carroll / Endpoint News

The steady migration of top R&D execs out of Big Pharma and into little biotech is continuing this morning. After spending the last decade in Big Pharma R&D, Chris Carpenter is making the leap to biotech, joining the rising star Rubius as chief medical officer.

The thinking process behind biopharma companies’ outsourcing management

Angus Liu / Fierce Pharma

How do biopharma companies choose the right CROs to run their clinical studies? What do sponsors need to do to ensure a smooth collaboration? Do they care about oversight? Through this brief summary of some presentations made by biopharma executives at this year’s Drug Development Forum, we offer some practical advice for sponsors on how to manage a smooth outsourcing relationship, and, for CROs, a peek into sponsors’ decision-making processes.

A plant of disposable medical devices opened in Dubna SEZ

GMP News

September 27 marked the opening of a plant for manufacturing sterile disposable medical devices in Dubna Special Economic Zone (SEZ). This socially important project implemented by PASCAL MEDICAL, one of the “anchor” residents of Dubna SEZ, is aimed at import substitution of medical products in Russia. 

Russian scientists isolated a phytocomplex with persistent analgesic effect

GMP News

The researchers of phytochemistry laboratory at the Siberian Botanic Garden of Tomsk State University, together with the oncopharmacology laboratory of E.D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, explored the properties of a flavonoid complex isolated from the above-ground part of Lychnis chalcedonica, a perennial plant.

Biotech researchers chart progress in fighting substance abuse

Arlene Weintraub / FierceBiotech

As the opioid crisis broadens by the day, the biotech community is doubling down on its efforts to solve the mystery of addiction—and find new ways to combat it. Toward that end, two sets of researchers announced progress this week advancing research aimed at targeting addiction centers in the brain.

EMA released update on its Post-Brexit relocation

GMP News

European Medicines Agency staff survey indicates that the future of public health in Europe is at stake. To complement the European Commission’s assessment of all bids for the relocation of the Agency submitted by Member States that will be published later this month, EMA is making available the results of its most recent staff retention survey, which raised serious concerns.

EMA warns Brexit may permanently damage its capabilities

Nick Paul Taylor / FierceBiotech

Global players of pharmaceutical industry are interested in the Russian market

GMP News

In October, the inter-agency commission will examine 3 projects of pharmaceutical companies that expressed a desire to conclude special investment contracts in the area of pharmaceutical industry. This was announced by Sergey Tsyb, the Deputy Minister of Industry and Trade of the Russian Federation.

August shipments of Russian pharmaceutical manufacturers increased by 34%

GMP News

In January-February 2017, Russian pharmaceutical manufacturers shipped from their warehouses the medicinal products in the amount of 212.3 billion rubles (ex warehouse prices, including VAT). In terms of rubles, this amounted to impressive 8.7% growth compared to the same period of the previous year.

Pfizer's fast-growing Ibrance romps toward an early $5B payoff: analyst

Tracy Staton / FiercePharma

The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. That’s despite Ibrance’s competition from newcomer Kisqali, a Novartis drug, and the forthcoming Lilly med abemaciclib. Or so says Morgan Stanley analyst David Risinger, who put out a research note this week saying the Pfizer med has advantages over its new competitors, even beyond its first-to-market status.